Circulating Dipeptidyl Peptidase 3 Modulates Systemic and Renal Hemodynamics Through Cleavage of Angiotensin Peptides

Hypertension. 2024 Apr;81(4):927-935. doi: 10.1161/HYPERTENSIONAHA.123.21913. Epub 2024 Feb 9.

Abstract

Background: High circulating DPP3 (dipeptidyl peptidase 3) has been associated with poor prognosis in critically ill patients with circulatory failure. In such situation, DPP3 could play a pathological role, putatively via an excessive angiotensin peptides cleavage. Our objective was to investigate the hemodynamics changes induced by DPP3 in mice and the relation between the observed effects and renin-angiotensin system modulation.

Methods: Ten-week-old male C57Bl/6J mice were subjected to intravenous injection of purified human DPP3 or an anti-DPP3 antibody (procizumab). Invasive blood pressure and renal blood flow were monitored throughout the experiments. Circulating angiotensin peptides and catecholamines were measured and receptor blocking experiment performed to investigate the underlying mechanisms.

Results: DPP3 administration significantly increased renal blood flow, while blood pressure was minimally affected. Conversely, procizumab led to significantly decreased renal blood flow. Angiotensin peptides measurement and an AT1R (angiotensin II receptor type 1) blockade experiment using valsartan demonstrated that the renovascular effect induced by DPP3 is due to reduced AT1R activation via decreased concentrations of circulating angiotensin II, III, and IV. Measurements of circulating catecholamines and an adrenergic receptor blockade by labetalol demonstrated a concomitant catecholamines release that explains blood pressure maintenance upon DPP3 administration.

Conclusions: High circulating DPP3 increases renal blood flow due to reduced AT1R activation via decreased concentrations of circulating angiotensin peptides while blood pressure is maintained by concomitant endogenous catecholamines release.

Keywords: DPP3 protein, human; angiotensin II; blood pressure; catecholamines; circulatory failure; procizumab; renal blood flow; renin–angiotensin system.

MeSH terms

  • Angiotensin II / pharmacology
  • Animals
  • Catecholamines
  • Dipeptidyl-Peptidases and Tripeptidyl-Peptidases / pharmacology
  • Hemodynamics*
  • Humans
  • Male
  • Mice
  • Peptides* / pharmacology

Substances

  • Peptides
  • Angiotensin II
  • Catecholamines
  • Dipeptidyl-Peptidases and Tripeptidyl-Peptidases